TaiGen Biotechnology Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 51

Employees

  • Stock Symbol
  • 4157

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.23
  • (As of Friday Closing)

TaiGen Biotechnology General Information

Description

TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7th Floor, 138 Shin Ming Road
  • Neihu District
  • Taipei, 114
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
ROCO
Vertical(s)
Corporate Office
  • 7th Floor, 138 Shin Ming Road
  • Neihu District
  • Taipei, 114
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TaiGen Biotechnology Stock Performance

As of 20-Nov-2026, TaiGen Biotechnology’s stock price is $0.23. Its current market cap is $161M with 712M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.23 $0.24 $0.22 - $0.52 $161M 712M 1.07M

TaiGen Biotechnology Financials Summary

As of 30-Sep-2026, TaiGen Biotechnology has a trailing 12-month revenue of $8.33M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 170,150 279,714 219,618 330,943
Revenue 8,326 8,318 4,695 3,953
EBITDA 5,095 1,863 (967) 4,875
Net Income 4,846 1,448 (1,202) 4,390
Total Assets 32,541 37,324 35,710 40,023
Total Debt 315 1,574 1,785 2,431
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TaiGen Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TaiGen Biotechnology‘s full profile, request access.

Request a free trial

TaiGen Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the sel
Drug Discovery
Taipei, Taiwan
51 As of 2014

Rahway, NJ
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TaiGen Biotechnology Competitors (25)

One of TaiGen Biotechnology’s 25 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Gilead Formerly VC-backed Foster City, CA
Genentech Formerly VC-backed South San Francisco, CA
Amgen Formerly PE-Backed Thousand Oaks, CA
You’re viewing 5 of 25 competitors. Get the full list »

TaiGen Biotechnology Patents

TaiGen Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023296430-A1 Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor Active 27-Jun-2022
AU-2023296430-B2 Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor Active 27-Jun-2022
EP-4543451-A1 Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor Pending 27-Jun-2022
EP-4543451-A4 Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor Pending 27-Jun-2022
US-20230414612-A1 Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor Pending 27-Jun-2022 A61K9/1652
To view TaiGen Biotechnology’s complete patent history, request access »

TaiGen Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TaiGen Biotechnology Investments (2)

TaiGen Biotechnology’s most recent deal was a Later Stage VC with GPCR Therapeutics. The deal was made on 28-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GPCR Therapeutics 28-Nov-2023 Later Stage VC Drug Discovery
Dongguan HEC TaiGen Biopharmaceuticals 10-Jan-2017 Joint Venture Pharmaceuticals
To view TaiGen Biotechnology’s complete investments history, request access »

TaiGen Biotechnology ESG

Risk Overview

Risk Rating

Updated February, 28, 2025

29.24 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view TaiGen Biotechnology’s complete esg history, request access »

TaiGen Biotechnology FAQs

  • When was TaiGen Biotechnology founded?

    TaiGen Biotechnology was founded in 2001.

  • Where is TaiGen Biotechnology headquartered?

    TaiGen Biotechnology is headquartered in Taipei, Taiwan.

  • What is the size of TaiGen Biotechnology?

    TaiGen Biotechnology has 51 total employees.

  • What industry is TaiGen Biotechnology in?

    TaiGen Biotechnology’s primary industry is Drug Discovery.

  • Is TaiGen Biotechnology a private or public company?

    TaiGen Biotechnology is a Public company.

  • What is TaiGen Biotechnology’s stock symbol?

    The ticker symbol for TaiGen Biotechnology is 4157.

  • What is the current stock price of TaiGen Biotechnology?

    As of 20-Nov-2026 the stock price of TaiGen Biotechnology is $0.23.

  • What is the current market cap of TaiGen Biotechnology?

    The current market capitalization of TaiGen Biotechnology is $161M.

  • What is TaiGen Biotechnology’s current revenue?

    The trailing twelve month revenue for TaiGen Biotechnology is $8.33M.

  • Who are TaiGen Biotechnology’s competitors?

    Merck & Co., Gesynta Pharma, Gilead, Genentech, and Amgen are some of the 25 competitors of TaiGen Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process